A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-...
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights•This was a phase 3 randomized, double-blind PCV20 study in adults 18–49 years old. •The immunogenicity of 3 PCV20 lots was evaluated and safety of PCV20 was described. •Equivalence of vaccine responses was observed for 20 serotypes across 3 PCV20 lots. •All of the PCV20 lots elicited robust immune responses to the vaccine serotypes. •Saf...
Alternative Titles
Full title
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2555965989
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2555965989
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2021.07.004
